EP Patent

EP3973959A1 — Treatment of cholestatic pruritus with seladelpar

Assigned to CymaBay Therapeutics Inc · Expires 2022-03-30 · 4y expired

What this patent protects

Treatment of cholestatic pruritus by therapy with seladelpar or a salt thereof.

USPTO Abstract

Treatment of cholestatic pruritus by therapy with seladelpar or a salt thereof.

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: EP3973959A1
Jurisdiction: EP
Classification: —
Expires: 2022-03-30
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.